Hepatitis C Side Effect Management: Lauren Thomas, RN, NP-C with Liver Specialists of Texas
by Dr. Joe Galati on September 26, 2011
Lauren Thomas, RN, NP-C, discusses in the video the management of side effects associated with hepatitis C therapy. The triple therapy, which includes pegylated interferon, ribavirin and a protease inhibitor (either telaprevir or boceprevir) are discussed. This video is geared for patients, family members, and healthcare providers involved in the care of hepatitis C patients and their treatment. Proper management of the medication side effects if key to successful treatment, and clearance of the HCV virus. Your comments are welcomed, letting us know what additional topics you would like included in the educational series.
Also See Hepatitis C Drug Incivek (telaprevir); What are the side effects ?
Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch
WATERTOWN, Mass., Sept. 26, 2011 /PRNewswire/ --
Enanta Pharmaceuticals, Inc. announced today that its lead development candidate from its NS5A hepatitis C virus (HCV) inhibitor program, EDP-239, has been recognized on Windhover's list of the "Top 10 Most Interesting Infectious Disease Projects to Watch." EDP-239 was chosen by independent experts at Windhover Information and Herndon Company.
NS5A, a clinically-validated target, is a non-structural viral protein that is essential to viral replication. Research efforts have shown that targeting NS5A gives rise to profound antiviral activity, and as a result, this protein has emerged as an important target for antiviral drug development. Enanta's NS5A program and intellectual property estate in the HCV field were derived from its internal drug discovery efforts.
"Enanta appreciates Windhover's recognition of our EDP-239 program for HCV, which showcases the strength of our internal drug discovery efforts aimed against important infectious disease targets," said Jay Luly, Ph.D, president and chief executive officer, Enanta Pharmaceuticals. "We are on-track to initiate a Phase 1 clinical trial for EDP-239 in the coming months, following preclinical studies that demonstrated picomolar potency against multiple genotypes of the virus, an excellent safety profile and a preclinical pharmacokinetic profile amenable to once-a-day dosing in humans."
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive infectious disease opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."
About the Hepatitis C Virus
Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death. Liver disease associated with HCV infection is growing rapidly, and there is an acute need for new therapies that are safer and more effective. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease and NS5A inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.
About Enanta
Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field. Enanta is developing novel protease, NS5A, nucleoside(tide) polymerase, and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include overcoming resistance to superbugs, treating respiratory tract infections, and developing intravenous and oral treatments for hospital and community MRSA infections. Enanta is a privately held company headquartered in Watertown, Mass. Enanta's news releases and other information are available on the company's web site at http://www.enanta.com/.
For Enanta Investor Relations, please contact:Paul Mellett617-607-0761
For Enanta Public Relations, please contact MacDougall Biomedical Communications:Kari Watson508-647-0209 or kwatson@macbiocom.com
SOURCE Enanta PharmaceuticalsBack to top
RELATED LINKS http://www.enanta.com/
From NATAP
Recruiting A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-333 and Ribavirin (RBV) in Treatment-Naive and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Images in Clinical Medicine
Porphyria Cutanea Tarda
Chih-Chieh Chan, M.D., and Sung-Jan Lin, M.D., Ph.D.
N Engl J Med 2011; 365:1128
September 22, 2011
A 51-year-old man with a history of heavy alcohol use, chronic hepatitis C virus (HCV) infection, and hepatic cirrhosis presented to his physician with an 8-month history of periorbital hair growth. On examination, healing crusts and scars were evident in sun-exposed areas. He described skin photosensitivity and intermittent painful blistering over the nape of the neck, the forearms, and the backs of the hands (Panel A).
The patient's urine had pink fluorescence under a Wood's lamp, suggesting the presence of uroporphyrin (Panel B, a urine sample from the patient [indicated by an asterisk] and one from a normal control subject [N] under white light; Panel C, the same two urine samples under ultraviolet A light). A diagnosis of porphyria cutanea tarda was confirmed when marked uroporphyrinuria was shown on laboratory analysis. Porphyria cutanea tarda results from decreased activity of the uroporphyrinogen decarboxylase enzyme. Although the mechanism is unknown, the sporadic form of the disease is strongly associated with chronic HCV infection. Facial hypertrichosis is common and may serve as a diagnostic clue.
Although treatment of the patient's chronic HCV infection was considered inadvisable by his hepatologist, low-dose oral hydroxychloroquine, skin photoprotection, and alcohol cessation successfully controlled the cutaneous eruptions within 6 months.
Chih-Chieh Chan, M.D.Sung-Jan Lin, M.D., Ph.D.National Taiwan University Hospital, Taipei,
Taiwan 009015@ntuh.gov.tw
New Hepatitis C Drugs
Published on Sep 19, 2011 by wdsutv
According to the Centers for Disease Control, an estimated 3.2 million americans have chronic Hepatitis C infections. The FDA recently approved two new drugs for treatment.
HIV
Rapid Immune Test Cuts HIV Care Drop-Outs
By eliminating bottlenecks, a rapid immune system test sharply cut the proportion of people who dropped out of HIV care before starting treatment, researchers reported.
Transplant
Old, diseased organs no barrier to donation
by: Marianne Betts
From: Herald Sun
September 26, 2011 12:00AM
ORGANS from old and diseased donors are increasingly being transplanted into gravely ill Australians.
The oldest donor last year was 84, and record numbers of organs are being transplanted from donors with cancer, diabetes and hepatitis, the Australian and New Zealand Organ Donation Registry 2011 Report reveals.
Despite an increase in organ donations, 1600 Australians are awaiting a transplant and many will die before they get one.
Last year, half the nation's 309 donors had been smokers, 14 had cancer, 20 had hepatitis B, two had hepatitis C, 29 had diabetes and 86 had high blood pressure.
In Australia, hepatitis B and C, cancer and the arenavirus have been passed on through infected donor organs and recipients have died.
Nine livers were transplanted from donors with hepatitis B or C.
Austin Hospital liver transplant unit director Professor Bob Jones said while some recipients might not have had hepatitis, others already would have had the disease.
He said there was a risk of hepatitis being passed from donor to recipient through a transplant.
"It's all about balancing the degree of risk - you have to balance these risks versus the risk of dying waiting," he said.
"If a patient is dying in ICU and has 24 hours to live and the only donor has hepatitis B, we will discuss it with the family."
Some elderly donors were suitable - a dying 30-year-old woman received a 78-year-old's liver, and two or three years later, it was still working "beautifully", he said.
Royal Australasian College of Surgeons transplant surgery chair Jonathan Fawcett said each year the average age of donors was rising.
"In the mid-1990s, (surgeons) were reluctant to use organs retrieved from donors over 50, but now it's common to use organs from donors well into their 60s," Mr Fawcett said.
Victorian medical director of organ and tissue donation Dr Helen Opdam said: "Ten years ago, we would not entertain using organs from someone who was a heavy smoker or a heavy drinker. "Now we will, as long as they are functioning well."
Marijuana
Prescription for Pot - A Debate on the Merits of Medical Marijuana
The use of marijuana for medicinal purpose has been a hotly debated topic in the United States. While cannabis is still listed as an illegal narcotic under Federal Law, 16 states and the District of Columbia have statutes decriminalizing medicinal marijuana as a therapy for specific ailments. Recently, the American Medical Association released a report urging review of marijuana as a Schedule 1 controlled substance, noting that physicians should be protected from prosecution for recommending marijuana and that further studies should be conducted into marijuana’s use as medicine.To provide further insight on this controversy, MD Magazine Peers & Perspectives convened two leading experts in the field to debate the merits or lack thereof of medical marijuana: Joel W. Hay, PhD, professor of clinical pharmacology and pharmaceutical economics and policy at the Shafer Center for Health Policy and Economics in the School of Pharmacy at the University of Southern California, and Joseph I. Sirven, MD, professor and chairman of the department of neurology at the Mayo Clinic in Arizona. The panel was moderated by Peter Salgo, MD. This transcript has been condensed and edited for clarity and length...Continue Reading
Pharmaceutical
Podcast: Dollars for Docs Update
by Minhee ChoProPublica, Sep. 19, 2:44 p.m.
ProPublica’s Charles Ornstein, Tracy Weber and Dan Nguyen join the podcast this week to talk about their recently updated Dollars for Docs database – a project tracking big pharma’s payments to physicians.
ProPublica recently published a major update to our Dollars for Docs news application [1] – a database tracking money physicians have received from some of the pharmaceutical industry’s largest companies to promote their products.
Currently, the database lists $761.3 million in payments from 12 companies, which account for about 40 percent of U.S. sales. But in 2013, all drug and medical device companies will have to disclose what they are paying doctors for promotional talks, consulting, research, meals and more. Until then, ProPublica’s Dollars for Docs team – Charles Ornstein, Tracy Weber and Dan Nguyen – hope their project will shed some light on the industry’s ties to physicians. They join the podcast this week to explain the technical complexity of this project, why pharmaceutical companies enlist physicians to promote their products to begin with, and why patients have a right to know this information.
Click Below To Listen Or Read Transcript
No comments:
Post a Comment